Taysha Gene Therapies (NASDAQ:TSHA) Given New $8.00 Price Target at Canaccord Genuity Group

Taysha Gene Therapies (NASDAQ:TSHA) had its target price upped by Canaccord Genuity Group from $6.00 to $8.00 in a research note released on Friday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

A number of other research firms also recently issued reports on TSHA. Needham & Company LLC restated a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $6.63.

Taysha Gene Therapies Trading Down 9.3 %

NASDAQ:TSHA opened at $2.06 on Friday. The stock’s 50 day moving average price is $1.98 and its 200 day moving average price is $2.38. The company has a market capitalization of $422.18 million, a PE ratio of 3.27 and a beta of 0.44. The company has a quick ratio of 5.22, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a 52-week low of $1.19 and a 52-week high of $4.32.

Institutional Trading of Taysha Gene Therapies

Several hedge funds have recently modified their holdings of TSHA. Creative Planning acquired a new stake in shares of Taysha Gene Therapies in the 3rd quarter valued at approximately $28,000. Principal Financial Group Inc. purchased a new position in Taysha Gene Therapies in the 2nd quarter valued at approximately $48,000. China Universal Asset Management Co. Ltd. increased its stake in Taysha Gene Therapies by 79.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after purchasing an additional 17,446 shares in the last quarter. Intech Investment Management LLC purchased a new position in Taysha Gene Therapies in the 3rd quarter valued at approximately $85,000. Finally, Scientech Research LLC purchased a new position in Taysha Gene Therapies in the 2nd quarter valued at approximately $97,000. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.